Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Sandy Srinivas, MBBS, Stanford Cancer Center
Advertisement
Articles by Sandy Srinivas, MBBS, Stanford Cancer Center
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Advertisement
Latest Updated Articles
Optimizing Use of PSMA PET Imaging and PSADT in Prostate CancerPublished: March 30th 2022 | Updated:
Adjuvant Therapy Approaches for Operable RCCPublished: August 10th 2021 | Updated:
Frontline Metastatic RCC: Nivolumab Plus CabozantinibPublished: July 13th 2021 | Updated:
Selecting Optimal Therapy for mHSPC: Design of the ARASENS TrialPublished: April 27th 2022 | Updated:
Overview of Improvements in Prostate Cancer ManagementPublished: March 30th 2022 | Updated:
Overview of Treatment for Metastatic HSPCPublished: April 20th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5